MaxCyte
MaxCyte's revenue fell 14.5% to $33 million in fiscal 2025. Its operating margin was −157.1%, down from −132.5% a year earlier. Free cash flow was −$36 million. The diluted share count rose 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
MaxCyte lost money in fiscal 2025: a net loss of $45 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 255 | 227 | 168 | 154 | 103 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3,368.3x | — | — | — | — |
| Current ratio | 17.3x | 16.4x | 10.7x | 10.9x | 8.3x |
| Quick ratio | 17.0x | 15.8x | 10.0x | 10.3x | 7.8x |
Cash flow
Projections
Project MaxCyte's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What MaxCyte says to expect
- End of 2026: total cash and investments
Assuming the close of the Akron acquisition, MaxCyte expects to have approximately $40.0 to $45.0 million in total cash, cash equivalents and investments as of the end of 2026, which accounts for an estimated $105.0 million paid in cash and acquisition deal expenses, along with $22.0 million drawn under the MidCap Financial credit facility financing.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $120,780 of MaxCyte shares on the open market, and 1 insider sold $8,316.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Maher MasoudPresident and CEO, Director | Bought | 100,000 | $1.21 | $120,780 | Form 4 |
| Mar 17, 2026 | Douglas J SwirskyChief Financial Officer | Sold | 10,142 | $0.82 | $8,316 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −68.2% | −82.2% | −124.0% |
| Altman Z'' | 7.62 | 6.40 | 3.25 |
| Accruals ratio | −5.8% | −5.3% | −4.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put MaxCyte side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MaxCyte | FY25 | −14.5% | −157.1% | −109.5% | — | — | — | |
| Rapid Micro Biosystems | FY25 | 19.7% | −141.1% | −95.0% | −192.8% | — | 2 | Compare |
| Bionano Genomics | FY25 | −7.4% | −117.0% | −57.3% | −89.9% | — | 5 | Compare |
| Alpha Teknova | FY25 | 7.3% | −41.9% | −24.2% | −22.0% | — | 5 | Compare |
| Precipio | FY25 | 29.8% | −5.0% | 1.5% | −7.8% | −37.4x | 7 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 22 | 26 | 34 | 44 | 41 | 39 | 33 |
| Revenue growth | — | 21.0% | 29.5% | 30.6% | −6.7% | −6.4% | −14.5% |
| Gross profit | 19 | 23 | 30 | 39 | 36 | 32 | 27 |
| Research and development | 18 | 18 | 15 | 20 | 24 | 22 | 21 |
| Operating income | −12 | −11 | −18 | −27 | −48 | −51 | −52 |
| Net income | −13 | −12 | −19 | −24 | −38 | −41 | −45 |
| Diluted EPS (US$) | −0.23 | −0.17 | −0.21 | −0.23 | −0.37 | −0.39 | −0.42 |
| Diluted shares (millions) | 56 | 70 | 91 | 102 | 103 | 105 | 106 |
| Cash flow | |||||||
| Cash from operations | −9 | −9 | −11 | −15 | −22 | −28 | −34 |
| Capital expenditure | 1 | 2 | 4 | 18 | 4 | 2 | 2 |
| Free cash flow | −10 | −11 | −15 | −33 | −25 | −29 | −36 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Stock-based compensation | 2 | 2 | 8 | 12 | 14 | 13 | 9 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 15 | 35 | 255 | 227 | 168 | 154 | 103 |
| Debt incl. finance leases | — | 5 | — | — | — | — | — |
| Total assets | — | 52 | 284 | 287 | 268 | 240 | 202 |
| Total liabilities | — | 19 | 21 | 33 | 36 | 33 | 31 |
| Shareholders' equity | 14 | 33 | 263 | 254 | 232 | 206 | 172 |
| Margins and ratios | |||||||
| Gross margin | 88.4% | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Operating margin | −57.4% | −42.2% | −53.7% | −61.8% | −117.0% | −132.5% | −157.1% |
| Net margin | −59.6% | −45.1% | −56.3% | −53.2% | −91.8% | −106.3% | −135.1% |
| Free cash flow margin | −46.6% | −41.5% | −42.8% | −75.2% | −61.5% | −75.8% | −109.5% |
| Rule of 40 (growth + FCF margin) | — | −20.4% | −13.3% | −44.6% | −68.2% | −82.2% | −124.0% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −12.9% | −9.1% | −15.6% | −18.7% | −23.6% |
| Return on assets | — | — | −11.4% | −8.3% | −13.7% | −16.2% | −20.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |